Circulating endothelial cells and progenitors in recurrent high-grade gliomas treated with bevacizumab and irinotecan.

M. Eoli, A. Calleri, L. Cuppini, E. Anghileri, S. Pellegatta, E. Prodi, M. G. Bruzzone, F. Bertolini and G. Finocchiaro

Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy; European Institute of Oncology, Milan, Italy; Fondazione IRCCS Istituto Neurologico, Milan, Italy

Abstract

Background: Bevacizumab (Bev), a monoclonal antibody targeting the vascular endothelial growth factor (VEGF), has shown significant activity in a subset of patients with high grade gliomas (HGG): to date no biological marker can predict the treatment benefit. Circulating endothelial cells (CEC) and progenitors (CEP) have been observed in cancer patients, reflecting ongoing tumor angiogenesis.

Methods: Forty-seven HGG patients (38 glioblastoma, GB; 9 anaplastic astrocytomas), relapsing after radiotherapy and temozolomide, were treated every 2 weeks with Bev (10 mg/kg) and irinotecan (125 or 340 mg/m² depending on EIAEDs use). Adverse events were graded based on the CTC-AE v3.0. Before first treatment and every 8 weeks MRI and CEC and CEP assessment were performed. Radiological responses were assessed based on RANO criteria. CEC and CEP were enumerated in healthy controls (n=37) and patients by six color flow cytometry as Syto+CD45-CD31+/P1h12+ and Syto+CD45-CD31+/CD133+ cells, respectively. The Kaplan Meier method estimated survival functions.

Results: Median age was 53 years (15-66), median Karnofsky Performance Status 70 (50-100). Median number of prior chemotherapy treatments: 2 (1-4). Median follow up: 6.5 months. Median PFS and OS were 6 and 10 months, respectively. For GB, 6M-PFS was 47% and 6M-OS 68%. No central nervous system hemorrhages were detected. No patients developed grade 3-4 hematological toxicity. One patient experienced a small intralesional bleeding. When compared to controls, HGG patients had a significantly lower CEC and CEP at baseline (88.5± 50 vs 140± 171, p= 0.03; 73.9 ± 62.3 vs 181± 167 p=0.001), but higher CD109+ CEC levels (91.5±78.3 vs 31±29). Interestingly, patients with higher baseline level of CEC, CEP and CD109+ CEC showed clinical benefit (i.e. PFS 4 months): 118.8 ± 57.4 vs 80.8±43.2, p=0.002; 99.7±74d vs 60.4±51.7, p=0.04; 126.8±97.1 vs 76.3±64, p=0.002. No correlation between baseline tumor volume, 6M-PFS and CEC or CEP enumeration was found.

Conclusions: Investigation on CEC and CEP could contribute to a better understanding of the action of Bev in HGG patients and help to identify responders.